share_log

LadRx (NASDAQ:CYTR) Earns Hold Rating From Analysts at StockNews.com

LadRx (NASDAQ:CYTR) Earns Hold Rating From Analysts at StockNews.com

LadRx（纳斯达克股票代码：CYTR）获得StockNews.com分析师的持有评级
kopsource ·  2022/12/27 02:02

StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a research report released on Friday morning. The brokerage issued a hold rating on the stock.

斯托克新闻网在周五上午发布的一份研究报告中开始报道LadRx(纳斯达克：Cytr-Get Rating)的股票。该券商对该股发布了持有评级。

LadRx Stock Up ∞

LadRx库存∞

NASDAQ:CYTR opened at $0.09 on Friday. LadRx has a 1 year low of $0.05 and a 1 year high of $0.86. The business has a 50 day simple moving average of $0.10 and a 200-day simple moving average of $0.13.

纳斯达克：Cytr上周五开盘报0.09美元。LadRx的一年低点为0.05美元，一年高位为0.86美元。该业务的50日简单移动均线切入位在0.10美元，200日简单移动均线切入位在0.13美元。

Get
到达
LadRx
LadRx
alerts:
警报：

About LadRx

关于LadRx

(Get Rating)

(获取评级)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
LadRx公司是一家生物制药研发公司，从事新型抗癌候选药物的发现、研究和临床开发。它专注于开发Linker激活药物释放(LADR)技术平台，这是一个发现引擎，可以帮助创建一条抗癌分子的管道，在避免不可接受的全身毒性的同时，将高效药物直接输送到肿瘤。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on LadRx (CYTR)
  • Three Healthcare Penny Stocks to Watch In The New Year
  • Southwest Airlines Stock, There is a Lot to Love
  • MarketBeat: Week in Review 12/19 – 12/23
  • These Steelmakers Deserve A Place On Your 2023 Watch List
  • Inflation Cools, Where Does The S&P 500 Go Now
  • 免费获取StockNews.com关于LadRx的研究报告(Cytr)
  • 新年值得关注的三只医疗保健便士股
  • 西南航空公司股票，有很多值得爱的东西
  • MarketBeat：回顾一周12/19-12/23
  • 这些钢铁制造商理应在2023年观察名单上占有一席之地
  • 通胀降温，标普500指数何去何从

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.

接收LadRx Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对LadRx和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发